zoledronic acid has been researched along with Prostatic Neoplasms, Castration-Resistant in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (65.63) | 24.3611 |
| 2020's | 11 (34.38) | 2.80 |
| Authors | Studies |
|---|---|
| Alshamsan, B; Alzahrani, M; Awan, A; Clemons, M; Liu, M; Ng, TL; Pond, G; Stober, C; Vandermeer, L | 1 |
| Anderson, M; Cao, Y; Chang, M; Rojas, V; Trieu, J; Varada, N; Vogelzang, NJ | 1 |
| Bratt, O; Carlsson, S; Fransson, P; Karlsson, CT; Kindblom, J; Stranne, J | 1 |
| Farooki, A; Lipitz-Snyderman, A; Meza, AM; Mitchell, AP; Morris, MJ; Panageas, KS | 1 |
| Chen, C; Fan, X; Guo, L; Huang, R; Lin, M; Qin, W; Xiang, S; Yu, D; Zhou, J | 1 |
| Abate-Daga, D; Benzaïd, I; Bishop, RT; Bustos, XE; Cianne, JE; de la Iglesia, J; Frieling, JS; Kim, Y; Li, T; Lo, CH; Lynch, CC; Ramello, MC; Roselli, E; Snedal, SA; Tordesillas, L; Wang, X | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM | 1 |
| Anton, A; Azad, A; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Pezaro, C; Semira, MC; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Cruz, C; Miyashita, H; Patel, V | 1 |
| Saad, F; Traboulsi, SL | 1 |
| Abernethy, AP; Finelli, A; Hernandez, RK; Lethen, J; Liede, A; Wade, S; Warner, D | 1 |
| Mulders, PFA; Niepel, D; Saad, F; Sternberg, CN; Tombal, BF | 1 |
| Bellarosa, C; Cardano, R; Dionisi, V; Fanti, S; Ghedini, P; Monari, F; Morganti, AG; Rizzini, EL | 1 |
| Body, JJ; Costa, L; Gonzalez-Suarez, E; Niepel, D; Terpos, E; von Moos, R | 1 |
| Body, JJ; Braun, A; Brown, JE; Chung, K; Cleeland, CS; Damyanov, D; Egerdie, B; Fallowfield, LJ; Marx, G; Palazzo, FG; Patrick, DL; Qian, Y; Stopeck, A; von Moos, R | 1 |
| Dellis, A; Papatsoris, AG | 1 |
| Irwig, MS | 1 |
| Bajory, Z; Bouzid, M; Cathomas, R; El Ghoneimy, A; Gillessen, S; Goncalves, F; Kacso, G; Kramer, G; Lesniewski-Kmak, K; Milecki, P; Pacik, D; Tantawy, W | 1 |
| Gartrell, BA; Saad, F | 1 |
| Chen, W; Jin, H; Pan, Y; Wang, F; Weng, Z; Ye, T; Yu, Z; Zheng, Y | 1 |
| Brown, J; Carducci, M; Damião, R; Fizazi, K; Goessl, C; Karsh, L; Massard, C; Milecki, P; Oudard, S; Rader, M; Shore, N; Smith, M; Wang, H; Ying, W | 1 |
| Beer, TM; Graff, JN | 1 |
| Body, JJ; Casimiro, S; Costa, L | 1 |
| Dellis, A; Papatsoris, A | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Assi, T; Bachour, M; El Rassy, E; Farhat, F; Ghosn, M; Kattan, J | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, LJ; Birtle, A; Brown, JE; Chakraborti, P; Collins, S; Daunton, A; Goranitis, I; Hussain, SA; James, ND; McLaren, D; O'Sullivan, JM; Parker, C; Pirrie, S; Pope, A; Porfiri, E; Russell, JM; Staffurth, J; Stanley, A; Wylie, J | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, L; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Goranitis, I; James, N; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, S; Pope, A; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J | 1 |
| Alibhai, SMH; Emmenegger, U; Finelli, A; Hotte, SJ; Morgan, SC; Walker-Dilks, C; Winquist, E; Zukotynski, K | 1 |
| Eastham, J; Saad, F; Segal, S | 1 |
14 review(s) available for zoledronic acid and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density; Denosumab; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Zoledronic Acid | 2022 |
Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and meta-analysis of randomized control trials.
Topics: Bone Neoplasms; Hormones; Humans; Male; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid | 2022 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid | 2020 |
The role of bone-targeted therapies for prostate cancer in 2017.
Topics: Androstenes; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
Topics: Abiraterone Acetate; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Taxoids; Zoledronic Acid | 2018 |
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid | 2019 |
Male hypogonadism and skeletal health.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Denosumab; Diphosphonates; Humans; Hypogonadism; Imidazoles; Immunologic Factors; Klinefelter Syndrome; Male; Men's Health; Osteoporosis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Testosterone; Zoledronic Acid | 2013 |
Management of bone metastases in patients with castration-resistant prostate cancer.
Topics: Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Interdisciplinary Communication; Male; Medical Oncology; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2014 |
Pathologic fracture in patients with metastatic prostate cancer.
Topics: Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Zoledronic Acid | 2014 |
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Enzyme Inhibitors; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Spinal Cord Compression; Zoledronic Acid | 2015 |
Targeting bone metastases in prostate cancer: improving clinical outcome.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoblasts; Osteolysis; Pain; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Zoledronic Acid | 2015 |
Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid | 2016 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Topics: Absorptiometry, Photon; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
9 trial(s) available for zoledronic acid and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Castration; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Zoledronic Acid | 2022 |
Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate.
Topics: Aged; Bone and Bones; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Zoledronic Acid | 2022 |
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Pain; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Young Adult; Zoledronic Acid | 2013 |
Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome; Zoledronic Acid | 2014 |
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Denosumab; Diphosphonates; Double-Blind Method; Hemoglobins; Humans; Imidazoles; Kallikreins; Male; Middle Aged; Multivariate Analysis; Peptides; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid | 2015 |
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diphosphonates; Docetaxel; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radiopharmaceuticals; Strontium; United Kingdom; Zoledronic Acid | 2017 |
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quality-Adjusted Life Years; Strontium Radioisotopes; Taxoids; Zoledronic Acid | 2016 |
Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2014 |
9 other study(ies) available for zoledronic acid and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Denosumab; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Sweden; Zoledronic Acid | 2022 |
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Humans; Male; Medicare; Osteoporotic Fractures; Prostatic Neoplasms, Castration-Resistant; United States; Zoledronic Acid | 2023 |
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer.
Topics: Animals; Cell- and Tissue-Based Therapy; Humans; Male; Mice; Prostatic Neoplasms, Castration-Resistant; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; United States; Zoledronic Acid | 2023 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Australia; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Docetaxel; Humans; Incidence; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2021 |
An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Cohort Studies; Denosumab; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Zoledronic Acid | 2018 |
Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome; Zoledronic Acid | 2019 |
Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Denosumab; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Zoledronic Acid | 2014 |